Related Experiment Video
Updated: May 17, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Venous thromboembolism in cirrhosis
Zhineng J Yang1, Karen A Costa, Enrico M Novelli
11Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Insights
Patients with cirrhosis face risks of bleeding and venous thromboembolic events (VTEs). This review clarifies that "autoanticoagulation" is a misnomer, highlighting the need for better VTE management in this population.
Area of Science:
- Hepatology
- Hematology
- Clinical Medicine
Background:
- Cirrhosis patients present a complex risk profile, susceptible to both bleeding and venous thromboembolic events (VTEs).
- The notion of cirrhosis conferring protection against thrombosis due to coagulation factor deficiencies is a misconception.
- This perceived "autoanticoagulation" can lead to underestimation of thrombotic risk in these patients.
Purpose of the Study:
- To examine the dual risk of bleeding and VTEs in patients with cirrhosis.
- To address the misconception of "autoanticoagulation" and its implications for thrombosis risk.
- To review the challenges and current understanding of VTE management and anticoagulation in cirrhosis.
Main Methods:
- Literature review focusing on VTE and anticoagulation in cirrhosis.
- Analysis of existing data on bleeding and thrombotic risks in cirrhotic patients.
- Examination of the concept of "autoanticoagulation" versus actual thrombotic risk.
Main Results:
- Cirrhosis patients exhibit a significant risk for VTEs, challenging the "autoanticoagulation" theory.
- Bleeding risk in cirrhosis complicates anticoagulation decisions.
- Current guidelines for VTE prophylaxis and treatment in cirrhosis are lacking.
Conclusions:
- The concept of "autoanticoagulation" in cirrhosis is inaccurate; these patients are at risk for thrombosis.
- Managing VTE in cirrhosis is clinically challenging due to the high bleeding risk.
- Further research into predictors of VTE is crucial for guiding anticoagulation strategies in cirrhosis.
Abstract:
The cirrhosis population represents a unique subset of patients who are at risk for both bleeding and developing venous thromboembolic events (VTEs). It has been commonly misunderstood that these patients are naturally protected from thrombosis by deficiencies in coagulation factors. As a result, the cirrhosis population is often falsely perceived to be "autoanticoagulated." However, the concept of "autoanticoagulation" conferring protection from thrombosis is a misnomer. While patients with cirrhosis may have a bleeding predisposition, not uncommonly they also experience thrombotic events. The concern for this increased bleeding risk often makes anticoagulation a difficult choice. Prophylactic and therapeutic management of VTE in patients with cirrhosis is a difficult clinical problem with the lack of clear established guidelines. The elucidation of laboratory and/or clinical predictors of VTE will be useful in this setting. This review serves to examine VTE and the use of anticoagulation in the cirrhosis population.
More Related Videos
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Portal Hypertension
Cirrhosis II: Pathophysiology
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Cirrhosis I: Introduction

